title: Fatal hepatic veno-occlusive disease in a phase I study of mylotarg and troxatyl in patients with refractory acute myeloid leukemia or myelodysplastic syndrome.
authors.affiliation: Department of Leukemia, University of Texas, M.D. Anderson Cancer Center, Houston 77030, USA. frankgiles@aol.com
authors.forename: Francis
authors.initials: F
authors.lastname: Giles
authors.forename: Guillermo
authors.initials: G
authors.lastname: Garcia-Manero
authors.forename: Susan
authors.initials: S
authors.lastname: O'Brien
authors.forename: Eihu
authors.initials: E
authors.lastname: Estey
authors.forename: Hagop
authors.initials: H
authors.lastname: Kantarjian
mesh_terms: D000208:Acute Disease; D000368:Aged; D000617:Aminoglycosides; D000900:Anti-Bacterial Agents / Q000009:adverse effects* / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D015703:Antigens, CD / Q000276:immunology; D015214:Antigens, Differentiation, Myelomonocytic / Q000276:immunology; D003596:Cytosine / Q000009:adverse effects* / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004148:Dioxolanes / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D000079982:Gemtuzumab; D006504:Hepatic Veno-Occlusive Disease / Q000209:etiology* / Q000401:mortality; D006801:Humans; D007951:Leukemia, Myeloid / Q000150:complications* / Q000188:drug therapy* / Q000276:immunology; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000150:complications* / Q000188:drug therapy* / Q000276:immunology; D063268:Sialic Acid Binding Ig-like Lectin 3
chemical_list: D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D015703:Antigens, CD; D015214:Antigens, Differentiation, Myelomonocytic; C571163:CD33 protein, human; D004148:Dioxolanes; D063268:Sialic Acid Binding Ig-like Lectin 3; C074908:troxacitabine; D003596:Cytosine; D000079982:Gemtuzumab